Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis.


Journal

Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575

Informations de publication

Date de publication:
20 08 2020
Historique:
received: 03 09 2019
accepted: 05 08 2020
entrez: 22 8 2020
pubmed: 21 8 2020
medline: 25 6 2021
Statut: epublish

Résumé

Metastasectomy is performed on a select cohort of patients with advanced and/or recurrent bone and soft tissue sarcomas because of the potential for long term relapse free and overall survival associated with the procedure. However, the evidence supporting metastasectomy is difficult to summarize without a systematic examination of existing literature. The objective of this systematic review will be to examine survival among both adults and children with advanced and recurrent bone and STS who undergo metastasectomy. We designed and registered a study protocol for a systematic review and meta-analysis. We will include data from survival studies (e.g., randomized trials, cohort studies, routine case registries, and case control) conducted in children and adults with advanced and recurrent bone and soft tissue sarcoma who undergo metastasectomy. The primary outcome will be overall survival. Secondary outcomes will be 30-day post-operative mortality, recurrence-free survival, time off systemic therapy, and patient-reported outcomes including quality of life end points where available. Literature searches will be performed in multiple electronic databases including Ovid MEDLINE ® (1946 to present), Ovid EMBASE (1974 to present), Web of Science, and Cochrane Library. Grey literature will be identified through searching references, conference abstracts, Papers First, and Google Scholar. Two investigators will independently screen all citations, full-text articles, and abstract data. Full-text articles selected for analysis will be assessed for quality and risk of bias. If feasible, we will conduct a random effects meta-analysis. Estimates will be stratified according to histology comparing survival based on organ of metastasectomy. Additional analysis will be conducted to explore the potential sources of heterogeneity according to various patient, disease, and treatment characteristics (e.g., metastasis status, age, disease burden, and concomitant interventions). This systematic review and meta-analysis will identify, evaluate, and integrate data on survival of metastasectomy of bone and soft tissue sarcoma by organ of metastasis. Our findings may have implications for clinicians, patients, and their families when considering selection for resection of oligometastatic disease in de novo, or recurrent bone and soft tissue sarcoma. Implications for future research will be identified to improve the outcomes of these complex patients. PROSPERO CRD42019126906.

Sections du résumé

BACKGROUND
Metastasectomy is performed on a select cohort of patients with advanced and/or recurrent bone and soft tissue sarcomas because of the potential for long term relapse free and overall survival associated with the procedure. However, the evidence supporting metastasectomy is difficult to summarize without a systematic examination of existing literature. The objective of this systematic review will be to examine survival among both adults and children with advanced and recurrent bone and STS who undergo metastasectomy.
METHODS
We designed and registered a study protocol for a systematic review and meta-analysis. We will include data from survival studies (e.g., randomized trials, cohort studies, routine case registries, and case control) conducted in children and adults with advanced and recurrent bone and soft tissue sarcoma who undergo metastasectomy. The primary outcome will be overall survival. Secondary outcomes will be 30-day post-operative mortality, recurrence-free survival, time off systemic therapy, and patient-reported outcomes including quality of life end points where available. Literature searches will be performed in multiple electronic databases including Ovid MEDLINE ® (1946 to present), Ovid EMBASE (1974 to present), Web of Science, and Cochrane Library. Grey literature will be identified through searching references, conference abstracts, Papers First, and Google Scholar. Two investigators will independently screen all citations, full-text articles, and abstract data. Full-text articles selected for analysis will be assessed for quality and risk of bias. If feasible, we will conduct a random effects meta-analysis. Estimates will be stratified according to histology comparing survival based on organ of metastasectomy. Additional analysis will be conducted to explore the potential sources of heterogeneity according to various patient, disease, and treatment characteristics (e.g., metastasis status, age, disease burden, and concomitant interventions).
DISCUSSION
This systematic review and meta-analysis will identify, evaluate, and integrate data on survival of metastasectomy of bone and soft tissue sarcoma by organ of metastasis. Our findings may have implications for clinicians, patients, and their families when considering selection for resection of oligometastatic disease in de novo, or recurrent bone and soft tissue sarcoma. Implications for future research will be identified to improve the outcomes of these complex patients.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42019126906.

Identifiants

pubmed: 32819423
doi: 10.1186/s13643-020-01445-z
pii: 10.1186/s13643-020-01445-z
pmc: PMC7441630
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

189

Références

Curr Oncol. 2020 Feb;27(Suppl 1):25-33
pubmed: 32174755
Am J Clin Oncol. 2018 Jul;41(7):681-686
pubmed: 27819879
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Ann Surg. 2000 Apr;231(4):500-5
pubmed: 10749609
Am J Clin Oncol. 2001 Apr;24(2):198-200
pubmed: 11319298
Ann Oncol. 2018 Apr 1;29(4):857-871
pubmed: 29432564
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
BMJ Open. 2012 Oct 08;2(5):
pubmed: 23048062
Cancer. 1996 Feb 15;77(4):675-82
pubmed: 8616759
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Thorac Cardiovasc Surg. 2006 Mar;54(2):120-3
pubmed: 16541354
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
pubmed: 10235518
Clin Epidemiol. 2013 May 16;5:147-62
pubmed: 23700373
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
pubmed: 18525458
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Semin Surg Oncol. 1990;6(5):297-302
pubmed: 2237090
Semin Oncol. 2008 Apr;35(2):134-46
pubmed: 18396199

Auteurs

Ying Wang (Y)

BC Cancer Vancouver, University of British Columbia, 600 West 10th Ave, Vancouver, V5Z 3E6, Canada.

Megan Delisle (M)

General Surgery Residency Program Department, University of Manitoba, 347-825 Sherbrook Street, Winnipeg, MB, R3T 2 N2, Canada.

Denise Smith (D)

Faculty of Health Sciences, Health Sciences Library, McMaster University, 1280 Main St W, Hamilton, Ontario, L8S 4 L8, Canada.

Amirrtha Srikanthan (A)

The Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H 8 L6, Canada. asrikanthan@toh.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH